In early September, pharmaceutical giant Novartis issued a press release that sent shock waves through the cardiology community. A drug called pelacarsen, once expected to be a potential blockbuster, had failed to reduce the risk of heart problems and stroke in people with underlying cardiovascular disease. More muscle, less belly fat: mutations to a gene
